US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Singapore Airlines: 1 dead, others injured after London
BANGKOK (AP) — A Singapore Airlines flight hit severe turbulence over the Indian Ocean and descended2024-05-22Experts at Boao forum express optimism about AI but urge oversight
BOAO, Hainan, March 27 (Xinhua) -- Guest speakers of a panel discussion on artificial intelligence (2024-05-22Explainer: What do new productive forces mean?
BEIJING, Feb. 21 (Xinhua) -- Ever since Chinese President Xi Jinping introduced the term "new produc2024-05-22China's railways handle over 300 mln passenger trips in festival travel rush
BEIJING, Feb. 20 (Xinhua) -- More than 300 million passenger trips were made via China's railways fr2024-05-22Thailand welcomes the return of trafficked antiquities from New York's Metropolitan Museum
BANGKOK (AP) — Thailand’s National Museum hosted a welcome-home ceremony Tuesday for two ancient sta2024-05-22- The lead prosecutor in OJ Simpson's murder trial has been seen for the first time since the NFL star2024-05-22
atest comment